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Background: The optimal timing of salvage androgen deprivation therapy (ADT) for biochemical recurrence after
radical prostatectomy is controversial. We compared the outcomes of ultra-early versus early salvage ADT.
Methods: Among 855 patients undergoing radical prostatectomy at our institution between 2000 and 2012, we
identified 121 with adjuvant-treatment-naïve pT2-4N0M0 prostate cancer who received salvage ADT for biochemical
recurrence. These patients were divided into an ultra-early salvage ADT group (n = 51), who started salvage ADT before
meeting the standardized definition of biochemical recurrence in Japan (two consecutive prostate-specific antigen
[PSA] values ≥0.2 ng/ml), and an early salvage ADT group (n = 70) who started salvage ADT when they met the
definition. The ultra-early ADT group consisted of those who started salvage ADT with a single PSA value ≥0.2 ng/ml
(n = 30) or with two consecutive PSA values >0.1 ng/ml and rising (n = 21). The primary endpoint was biochemical
recurrence after salvage ADT, defined as a single PSA value ≥0.2 ng/ml after PSA nadir following salvage ADT. Secondary
endpoints were clinical metastasis and cancer-specific survival. A Cox proportional hazards model was used for
multivariate analysis. The median follow-up was 65.5 months.
Results: Biochemical recurrence occurred in one patient (2.0%) in the ultra-early group and in 12 (17.1%) in the
early salvage ADT group. Multivariate analysis identified ultra-early salvage ADT and preoperative Gleason score
≤7 as independent negative predictors of biochemical recurrence after salvage ADT. Only one patient in the early
salvage ADT group developed clinical metastasis to a left supraclavicular lymph node, and no patient died from prostate
cancer during follow-up. The major limitations of this study were its retrospective design, selection bias, and the possibility
that the ultra-early salvage ADT group may have included patients without biochemical recurrence.
Conclusions: Ultra-early salvage ADT was an independent negative predictor of biochemical recurrence after salvage
ADT in post-prostatectomy patients. Further consideration should be given to the use of salvage ADT before meeting the
current definition of biochemical recurrence.
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Approximately 25–35% of patients develop evidence of
biochemical recurrence after radical prostatectomy for
clinically localized prostate cancer [1,2]. Although salvage
androgen deprivation therapy (ADT) is a popular option
for the management of biochemical recurrence, uncer-
tainty remains regarding which patients benefit from early
salvage ADT and the ideal time at which to initiate
therapy [3]. A retrospective analysis of 1,740 patients
who underwent radical prostatectomy between 1990 and
1999 found no difference in systemic progression or
cancer-specific survival between men who started salvage
ADT at a prostate-specific antigen (PSA) level of ≥0.4 ng/
ml compared with those who did not receive salvage ADT
[4]. According to a similar analysis of 1,352 patients who
underwent radical prostatectomy between 1988 and 2002,
early salvage ADT for biochemical recurrence after radical
prostatectomy was an independent predictor of delayed
clinical metastases in high-risk cases, but not in the overall
cohort [5].
However, these studies were mainly conducted before
the era of ultrasensitive PSA assays, since when the def-
inition of biochemical recurrence has changed. For
example, Mir et al. recently advocated definitions of
biochemical recurrence as any PSA ≥0.05 ng/ml in pa-
tients with nomogram-predicted 5-year progression-
free probabilities of <50% [6].
We therefore compared the outcomes of early and very
early administration of salvage ADT in patients treated
with radical prostatectomy for localized prostate cancer.
Methods
We retrospectively reviewed 855 patients who under-
went radical prostatectomy at our institution between
2000 and 2012 and identified 121 patients with
adjuvant-treatment-naïve localized (pT2-4N0M0) pros-
tate cancer who subsequently received continuous sal-
vage ADT because of biochemical recurrence. Patients
who underwent radiotherapy prior to or concomitant
with hormonal therapy and patients who received any
neo-adjuvant therapy were excluded from the study.
The included patients were further divided into two
groups: an ultra-early salvage ADT group (n = 51), in
which patients started salvage ADT before meeting the
standardized definition of post-prostatectomy bio-
chemical recurrence in Japan (two consecutive PSA
values ≥0.2 ng/ml [7]); and an early salvage ADT group
(n = 70), in which patients started salvage ADT when
they met the definition. The ultra-early salvage ADT
group consisted of those who started salvage ADT with
a single PSA value ≥0.2 ng/ml (n = 30) or with two con-
secutive PSA values >0.1 ng/ml and rising (n = 21). Pa-
tient allocation was not randomized. Doctors generally
recommended early salvage ADT according to the GeneralRule for Clinical and Pathological Studies on Prostate
Cancer of the Japanese Urological Association [8], but
some patients were anxious and chose to have ultra-early
salvage ADT. The clinicopathologic backgrounds of the
two groups were similar, and the median durations of
salvage ADT were 41 months in the ultra-early and
46 months in the early salvage ADT groups, respectively
(Table 1). Patients who discontinued salvage ADT were
treated as censored at the point of discontinuation. The
median follow-up for all patients was 65.5 months (inter-
quartile range [IQR]: 46–90.5 months) after radical pros-
tatectomy, and an average of 33 PSA values were available
per patient (i.e. total of 3,957 PSA values). We began using
ultrasensitive PSA assays in September 2003.
The primary endpoint was biochemical recurrence
after salvage ADT, defined as a confirmed single PSA
value ≥0.2 ng/ml after PSA nadir following salvage
ADT. Secondary endpoints were clinical metastasis and
cancer-specific survival. Univariate analysis was con-
ducted using the log-rank test and multivariate analysis
was performed using the Cox proportional hazards
model. All statistical analyses were carried out using
JMP version 9.0.2 (SAS Institute, Cary, NC, USA). A
value of p < 0.05 was considered significant.
This study was approved by the Ethics Committee,
Graduate School of Medicine and Faculty of Medicine,
The University of Tokyo. Written informed consent
for participation in this study was obtained from all
participants.
As of 2014, the standardized definition of biochemical
recurrence after radical prostatectomy in Japan was two
consecutive PSA values ≥0.2 ng/ml at intervals of 2–4
weeks, as stated above [7], which is one of six standard
definitions that have been used in published studies or
are in current clinical use [6].
Results
One of 51 (2.0%) patients in the ultra-early salvage ADT
group developed biochemical recurrence, compared with
12 of 70 (17.1%) patients in the early salvage ADT group
(Figure 1). Univariate analysis demonstrated that timing
of treatment (ultra-early salvage ADT versus early sal-
vage ADT, p = 0.0279), preoperative PSA value (<20 ng/
ml versus ≥20 ng/ml, p = 0.0493), and pathologic Glea-
son score (≤7 versus ≥8, p = 0.0043) were associated with
the risk of biochemical recurrence after salvage ADT
(Table 2).
Multivariate analysis identified ultra-early salvage ADT
(p = 0.0118) and preoperative Gleason score ≤7 (p =
0.0182) as independent negative predictors of biochem-
ical recurrence after salvage ADT (Table 3).
Regarding secondary endpoints, only one patient from
the early salvage ADT group developed clinical metasta-
sis to a left supraclavicular lymph node (p = 0.4233, log-
Figure 1 Kaplan-Meier curve depicting biochemical recurrence-free survival in patients treated with ultra-early versus early
salvage ADT.
Table 1 Clinicopathologic characteristics of patients treated with ultra-early or early salvage ADT
Variable Ultra-early salvage ADT (n = 51) Early salvage ADT (n = 70) p-value
Median age at prostatectomy, yr (IQR) 65 (61 - 69) 67 (60.75 - 72.25) 0.2992
Age at prostatectomy, no. (%): 0.0804
<70 yr 39 (76.5) 43 (61.4)
≥70 yr 12 (23.5) 27 (38.6)
Median preoperative PSA, ng/ml (IQR) 10.65 (7.3 - 15.56) 9.55 (6.3 - 12.07) 0.1903
Preoperative PSA, no (%): 0.6041
<20 ng/ml 46 (90.2) 61 (87.1)
≥20 ng/ml 5 (9.8) 9 (12.9)
Pathologic Gleason score, no. (%): 0.3256
≤6 12 (23.5) 23 (32.9)
7 28 (54.9) 38 (54.3)
8-10 11 (21.6) 9 (12.9)
Pathologic tumor stage, no. (%): 0.8619
T2 32 (62.7) 45 (64.3)
T3/4 19 (37.3) 25 (35.7)
Extraprostatic extension, no. (%) 17 (33.3) 25 (35.7) 0.7859
Lymphovascular invasion, no. (%) 13 (25.5) 16 (22.9) 0.7376
Positive resection margin, no. (%) 37 (72.5) 43 (61.4) 0.2019
Seminal vesicle invasion, no. (%) 2 (3.9) 2 (2.9) 0.7464
Perineural invasion, no. (%) 35 (68.6) 43 (61.4) 0.4139
Median duration time of salvage ADT, months (IQR) 41 (22 - 66) 46 (27 - 73.25) 0.1326
ADT, androgen deprivation therapy; PSA, prostate-specific antigen; IQR, interquartile range.
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Table 2 Univariate analysis of the impact of various
clinicopathologic factors on the risk of biochemical
recurrence after salvage ADT
No. of patients p-value
Treatment group 0.0279*
Ultra-early salvage ADT 51




Preoperative PSA, ng/ml 0.0493*
<20 107
≥20 14
Pathologic Gleason score 0.0043*
≤7 101
≥8 20









Positive resection margin 0.4467
0 41
1 80






ADT, androgen deprivation therapy; *statistically significant; PSA,
prostate-specific antigen.
Table 3 Multivariate Cox proportional hazards regression
analysis evaluating the impact of various
clinicopathologic factors on the risk of biochemical
recurrence after salvage ADT
HR (95% CI) p-value
Treatment group
Ultra-early salvage ADT Reference
Early salvage ADT 7.691 (1.466-141.6) 0.0118*
Preoperative PSA, ng/ml
<20 Reference
≥20 2.065 (0.529-6.761) 0.2744
Pathologic Gleason score
≤7 Reference
≥8 4.739 (1.330-15.73) 0.0182*
ADT, androgen deprivation therapy; *statistically significant; PSA,
prostate-specific antigen.
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ing the follow-up period. We were therefore unable to
detect any differences in secondary endpoints between
the two groups. This might be because the follow-up
period was not long enough.
Discussion
ADT is a well-established treatment modality for patients
with advanced prostate cancer. However, despite its proven
efficacy in improving the quality of life in patients with
metastatic disease, there is currently no consensus re-
garding the optimal timing of ADT after definitive localtherapy [9]. Although a small randomized trial has sup-
ported the use of adjuvant ADT after radical prostatec-
tomy in the setting of lymph node metastases [10,11],
no randomized study has yet evaluated the utility of
ADT for failure after radical prostatectomy, especially
in patients without lymph node metastases [9].
Previous retrospective studies found no effect of salvage
ADT on systemic progression-free survival or cancer-
specific survival. Siddiqui et al. reviewed 1,740 patients
who underwent radical prostatectomy between 1990 and
1999 and compared various PSA thresholds in relation to
the timing of salvage ADT administration. They found no
advantage in terms of systemic progression-free survival or
cancer-specific survival in men who started salvage
ADT at a PSA of 0.4, 1.0, or 2.0 ng/ml compared with
those who did not receive salvage ADT [4]. A similar
analysis by Moul et al. of 1,352 patients who underwent
radical prostatectomy between 1988 and 2002 found
that early salvage ADT for biochemical recurrence after
radical prostatectomy was an independent predictor of
delayed clinical metastases in high-risk patients (Gleason
score ≥8 or PSA-doubling time ≤12 months), but had no
impact on clinical metastases in the overall cohort [5].
However, these studies were mainly conducted before
the era of ultrasensitive PSA assays. Ultrasensitive PSA as-
says allow a more precise measurement of ultrasensitive
PSA values, possibly resulting in an optimal definition of
biochemical recurrence after radical prostatectomy. For
example, Mir et al. recently advocated the use of biochem-
ical recurrence defined as any PSA ≥0.05 ng/ml in patients
with nomogram-predicted 5-year progression-free prob-
abilities of <50%, who might thereby benefit from early
salvage radiotherapy [6]. While radiotherapy has been
established as the most common salvage treatment for re-
currence after radical prostatectomy in Europe and the
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treatment in Asia. The Asia Consensus Statement 2013 in
the NCCN Clinical Practice Guidelines in Prostate Cancer
states that androgen deprivation is a candidate treat-
ment option for post-radical prostatectomy recurrence
in Asian patients negative for distant metastasis [12].
Indeed, radical prostatectomy and immediate adjuvant
androgen deprivation therapy achieved excellent re-
sults, including a 10-year cancer-specific survival rate
of 96.3% and 10-year estimated overall survival rate of
85.7% in Japanese patients with pT3N0 prostate cancer
after a median follow-up period of 8.2 years [13]. Never-
theless, studies concerning the optimal timing of salvage
ADT in the era of ultrasensitive PSA assays are lacking.
In the present study, patients who started salvage ADT
before meeting a currently accepted definition of bio-
chemical recurrence were less likely to develop subse-
quent biochemical recurrence after salvage ADT than
those who started salvage ADT when they met the defin-
ition. By its very nature, ADT is less likely to contribute to
local control than radiotherapy. However, ADT may im-
prove local control when the residual tumor burden is
very small, and adjuvant ADT after radical prostatectomy
improved the clinical outcome in patients with adverse
pathologic findings [10,11]. In a randomized prospective
controlled trial, Messing et al. demonstrated that adjuvant
ADT benefited patients with nodal metastases who had
undergone prostatectomy and lymphadenectomy, com-
pared with those who receive deferred treatment [10,11].
Referring to the results of European Organization for Re-
search and Treatment of Cancer (EORTC) trial 30846,
which found no benefit of immediate ADT compared with
deferred therapy in men without definitive local treatment
of the primary tumor [14], Messing et al. concluded that
ADT was probably most effective against very small tu-
mors [10,11,15]. The estimated tumor burden in EORTC
30846 was ≥12.5 cm3 of cancer tissue, which was the
mean local-tumor volume in Messing et al.’s patients [11].
Several experimental systems have provided collateral evi-
dence to support the benefit of early ADT in inhibiting
tumorigenesis [16-18].
A similar concept was recently demonstrated in the set-
ting of salvage radiotherapy. Briganti et al. reported that
timely administration of early salvage radiotherapy (given
at PSA ≤0.5 ng/ml) was comparable to adjuvant radiother-
apy for improving biochemical recurrence-free survival in
pT3N0 prostate cancer, and suggested that initial observa-
tion followed by early salvage radiotherapy delivered at
low PSA levels might be a viable option for the majority of
surgically-managed patients with pT3N0 prostate can-
cer [19]. The present study may imply that we should
consider using a PSA threshold below the currently ac-
cepted definition of biochemical recurrence in order to
maximize the benefit from salvage ADT. Together withan excellent result of adjuvant ADT post-prostatectomy
against pT3N0 prostate cancer [13], ADT might be
more efficacious than other treatments in small tumors.
However, ADT is associated with some real risks re-
lated to metabolic syndrome.
Our study had several limitations. The ultra-early sal-
vage ADT group may have included patients without evi-
dence of biochemical recurrence, which may have resulted
in overestimation of the outcomes of ultra-early salvage
ADT. Other limitations were its retrospective design, se-
lection bias, lead-time bias, small sample size, and the in-
clusion of only Japanese subjects. Randomized prospective
studies with longer follow-up periods are thus needed to
confirm the benefits of ultra-early salvage ADT.
Conclusions
Ultra-early salvage ADT is an independent negative pre-
dictor of biochemical recurrence after salvage ADT in
adjuvant-treatment-naïve pT2-4 pN0 M0 radical prosta-
tectomy patients. The currently accepted definition of
biochemical recurrence should be challenged in relation
to the optimal timing of initiating salvage ADT.
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